An in vivo model for study of the angiogenic effects of basic fibroblast growth factor.
We have investigated the angiogenic effects of basic fibroblast growth factor following its implantation in slow release beads under the kidney capsule. The presence of basic fibroblast growth factor in the subcapsular space induced a marked angiogenic response maximal at 1 microgram dose per kidney. Histological examination at the site of treatment failed to reveal evidence of an inflammatory response, thus supporting the observation that basic fibroblast growth factor alone can stimulate in vivo neovascularization. Beads pretreated with saline or with human growth hormone had no angiogenic effect. Because of the readily accessible location in the retroperitoneal space, the ease of drug delivery, and the marked vascular proliferation seen in response to FGF, our results suggest that the kidney capsule is an excellent model for study of the physiological role played by FGF and related peptides in promoting angiogenesis in vivo.
D000818:Animals; D004343:Drug Implants; D005346:Fibroblast Growth Factors / Q000008:administration & dosage / Q000494:pharmacology*; D007668:Kidney / Q000098:blood supply; D008297:Male; D008954:Models, Biological; D009389:Neovascularization, Pathologic; D051381:Rats; D011917:Rats, Inbred Lew
D004343:Drug Implants; D005346:Fibroblast Growth Factors